At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,229 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 7,229 participants.
Detailed Summary
The AGIL study was designed to evaluate the effectiveness and safety of adalimumab over 5 years in routine daily clinical practice in Germany, with a focus on the impact of therapy on employment-related outcomes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedFeb 2010
Primary CompletionSep 2017
TodayJul 2026
First PostedFeb 26, 2010
Enrollment StartJan 12, 2009
Primary CompletionSep 14, 2017
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 16.3 years ago